Over the past two decades, significant progress has been made in understanding the molecular mechanisms of cancer, which has led to the development of molecular targeted agents including tyrosine kinase inhibitors, antiangiogenic agents, cell cycle and signalling targeting compounds, PARP inhibitors, DNA methylation inhibitors and antibody-drug conjugates. For many cancers including leukaemia, melanoma, lung, colorectal and breast cancer, targeted therapies have transformed the repertoire of currently available treatments, such as Vemurafenib for BRAF mutated metastatic melanoma and Herceptin for HER2 overexpressing breast cancer. Yet, the responses to targeted therapies are only marginal and short-lived, since many cancers develop resistance leading to disease progression, in addition to patients experiencing toxic side effects and financial burdens associated with treatment.
To overcome the problems associated with tumour resistance, research is focused on developing combination strategies involving targeted therapies and next-generation inhibitors with enhanced efficacy and selectivity. At the same time, molecular approaches are warranted to identify biomarkers and select the most suitable patients to optimise benefit and minimise toxicity.
In recognition of the growing field of research, BMC Medicine and BMC Cancer come together to invite submissions of original research including but not limited to:
- Novel molecular targeted therapies, such as small molecules, antibodies and drug-antibody conjugates for new tumour targets
- Resistance to conventional targeted therapies or the development of novel therapeutic targets that overcome targeted therapy resistance
- Combination therapies involving targeted therapy
- Discovery of novel serum/tumor biomarkers relevant to targeted therapies in clinical cohorts (e.g. from clinical trials)
- Identification of genomic biomarkers relevant to targeted therapies through sequencing or bioinformatics (Please note: any bioinformatics studies must be experimentally validated or accompanied by real-world cohorts)
- Survivorship and toxicology in patients treated with targeted or combination therapy regimens
For more information about each participating journal, including article-processing charges, click on its title below. After submitting to a participating journal, each article will undergo that journal’s full standard peer review process.
BMC Medicine encourages submissions of front matter articles and original research including randomised clinical trials (phase I, I/II, II and III as well as positive or negative trials), clinical “Real World” studies, cost-effectiveness analysis, systematic reviews, medical imaging, genomic and serum biomarkers and translational research. For translational research we only consider studies that include patient cohorts or involves human samples. Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation will not be considered. BMC Medicine does not consider case reports.
Guest Editors provided guidance on the scope of this collection and advised on commissioned content. However, they are not involved in editorial decision-making on papers submitted to this collection. All final editorial decisions are with the Editor-in-Chief, Dr. Lin Lee.
BMC Cancer encourages submissions of original research and study protocols reporting on randomised clinical trials (phase I, I/II, II and III as well as positive or negative trials), “Real World” studies, systematic reviews, medical imaging, genomic and serum biomarkers and translational research. BMC Cancer does not consider case reports. For pre-clinical and experimental research, we only consider studies that provide results validated in at least 3 relevant cell lines, preferably validated in at least one animal model. Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation will not be considered.